Stallergenes Greer

Citryll Announces the Appointment of Maarten Kraan as Chief Medical Officer

Retrieved on: 
Tuesday, February 13, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, MSD, Therapy, Roche, Infliximab, Pfizer, AstraZeneca, Senior, Immune-mediated inflammatory diseases, Merck, Schering-Plough, CMO, Neutrophil, Research and development, Adalimumab, Inflammation, Belatacept, Leiden University, Stallergenes Greer, Bristol Myers Squibb, Abatacept, Rheumatoid arthritis, Hidradenitis suppurativa, Merck & Co., Patient, Pierre Fabre, Biology, Development, Pharmaceutical industry

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.
  • Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
  • Dr. Kraan will replace Dr. Patrick Round, who will continue to support the company during the transition period.
  • Notably, Dr. Kraan was also involved in the development of Orencia (abatacept), Remicade (infliximab), Humira (adalimumab) and fostamatinib for rheumatoid arthritis.

Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer

Retrieved on: 
Tuesday, December 12, 2023
Ipsen, Swedish Orphan Biovitrum, Myenteric plexus, Drug development, Albireo, Stallergenes Greer, Holding, Therapy, Suffolk University Law School, Dickinson College, Merck Serono, Patient, Acushnet Company, Management

WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Jason Duncan as chief legal officer.

Key Points: 
  • WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Jason Duncan as chief legal officer.
  • Mr. Duncan will be a member of Neumora’s Executive Team, reporting to Henry Gosebruch, chief executive officer, and will oversee all aspects of the Company’s legal and compliance functions.
  • Mr. Duncan has more than two decades of legal, compliance, development and operations experience in the life sciences industry.
  • I look forward to working with Neumora’s talented team as we seek to pioneer a new era in brain disease,” said Jason Duncan, chief legal officer, Neumora.

Stallergenes Greer Announces Global Agreement With Nestlé Regarding the Peanut Allergy Oral Immunotherapy Treatment Palforzia®

Retrieved on: 
Monday, September 4, 2023
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Tablet, Allergy, Stallergenes Greer, Prevalence, Patient, Peanut, Anaphylaxis, AIT, Pharmaceutical industry

Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announced today that it has signed global agreements with Nestlé to harness the peanut allergy oral immunotherapy treatment Palforzia®.

Key Points: 
  • Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announced today that it has signed global agreements with Nestlé to harness the peanut allergy oral immunotherapy treatment Palforzia®.
  • Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among children between 2005 and 20152.
  • “We are delighted about this agreement with Nestlé which marks a significant milestone for Stallergenes Greer,” stated Michele Antonelli, CEO of Stallergenes Greer.
  • By entering the food allergy space, Stallergenes Greer becomes the first allergen immunotherapy company to offer both respiratory and food allergy treatments and demonstrates its lasting commitment to provide patients and the medical community with innovative allergen immunotherapy treatments.”
    Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer.

Stallergenes Greer Foundation Science Awards for Allergy 2023: Call for Applications

Retrieved on: 
Thursday, June 8, 2023
Philanthropy, Health, Environment, Fund Raising, Foundation, General Health, Climate Change, Allergy, Doctor of Philosophy, Agropolis Fondation, Research, Stallergenes Greer, The Economist, Trustee, Physician, Medicine, Environmental Health (journal), Timeline, Forestry, Nursing, Pharmaceutical industry

The Stallergenes Greer Foundation aims to create healthier futures for all.

Key Points: 
  • The Stallergenes Greer Foundation aims to create healthier futures for all.
  • Submissions are open for the Stallergenes Greer Foundation Science Awards for Allergy 2023.
  • The Stallergenes Greer Foundation Science Awards for Allergy are presented in two areas:
    - Innovation Awards: two awards will be presented either to encourage and raise the profile of a young scientist (below 40 years of age) or to recognise the outstanding work of a mid-career scientist (with a 10–20-year track record), who are driving innovation in respiratory and food allergy.
  • Rules and regulations: Detailed guidelines regarding the Stallergenes Greer Foundation’s Science Awards for Allergy are available on the foundation’s website: https://stallergenesgreer-foundation.org

Stallergenes Greer Initiates a European Paediatric Phase III Study With Staloral® Birch

Retrieved on: 
Thursday, May 25, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Allergy, Asthma, AIT, Tree, Stallergenes Greer, Internal Coordinate Mechanics, Otorhinolaryngology, Patient, Risk, Birch, Medicine, Diagnosis, Young, Safety, Fatigue, Pharmaceutical industry, Vaccine

The randomised, double-blind placebo-controlled Phase III study will involve approximately 80 sites in 12 European countries.

Key Points: 
  • The randomised, double-blind placebo-controlled Phase III study will involve approximately 80 sites in 12 European countries.
  • The allergic potential of other trees belonging to the birch homologous group, such as alder and hazel, is also increasing steadily2.
  • “Allergic rhino-conjunctivitis induced by birch and related trees can lead to a spiraling of respiratory symptoms and conditions in the paediatric population.
  • “Stallergenes Greer’s AIT treatments have proven their efficacy and safety in both clinical trials and the real world,” stated Michele Antonelli, CEO of Stallergenes Greer.

Stallergenes Greer Foundation to Foster Innovation and Precision Medicine in the Field of Allergy

Retrieved on: 
Wednesday, April 26, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Infectious Diseases, Health Technology, Islamabad Wildlife Management Board, Allergy, Education, University Medical Center, Agropolis Fondation, Communication, Environmental health, Doctor of Philosophy, Stallergenes Greer, Associate, Teaching hospital, Harvard University, Asthma, Public health, Animal, MD, Bambino, University Hospital (Newark, New Jersey), Internal medicine, Medicine, Corporation, Environmental Health (journal), Diagnosis, Hospital, WHO, Penn State Board of Trustees, Management, Nursing, Natural rubber, Trustee

Stallergenes Greer, a biopharmaceutical company specialising in the research, diagnosis and treatment of respiratory allergies, is pleased to announce its strategic direction for the Stallergenes Greer Foundation.

Key Points: 
  • Stallergenes Greer, a biopharmaceutical company specialising in the research, diagnosis and treatment of respiratory allergies, is pleased to announce its strategic direction for the Stallergenes Greer Foundation.
  • I would like to take this opportunity to thank the members of our Scientific Board whose experience and vision are strong assets for the foundation,” stated Michele Antonelli, CEO of Stallergenes Greer and Chairman of the Stallergenes Greer Foundation.
  • The Stallergenes Greer Foundation will support innovative research projects, encompassing fundamental, applied, environmental and societal research, as well as education.
  • In 2023, the foundation will allocate up to €150,000 for outstanding work led either by a young scientist or a mid-career scientist to advance precision medicine in the field of allergy, or outstanding work in the environmental field to advance the prevention and treatment of allergies.

Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy With Imperial College London Research Collaboration

Retrieved on: 
Monday, January 17, 2022
Science, Research, Pharmaceutical, Health, Infectious Diseases, University, Education, Clinical Trials, Biomarker, Medicine, Patient, Research, Virology, AIT, Publication, International, Reuters, Precision medicine, COVID-19, Science, Knowledge, Immunomodulation, HIV disease progression rates, Rankings of universities in the United Kingdom, Disease, Student, NHS, Review, Industry, Allergy, Times Higher Education, Time, Diagnosis, Imperial, Immune system, College, Engineering, Stallergenes Greer, Imperial College London, Partnership, University, Pharmaceutical industry, Vaccine, Allergen Immunotherapy, Stallergenes Greer, Imperial College London, ALLERGEN IMMUNOTHERAPY, STALLERGENES GREER, IMPERIAL COLLEGE LONDON

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.

Key Points: 
  • Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.
  • This underscores our commitment to advancing precision medicine for allergy sufferers, stated Amer Jaber, Executive VP Operations Europe and International and President of Stallergenes SAS.
  • This research collaboration is a remarkable opportunity for a fruitful partnership between Imperial College London, a pioneer and world-leading university in the biomarker field, and Stallergenes Greer.
  • It will build on the recent advances of biomarker research to further develop precision medicine in AIT for the benefit of patients with allergic diseases, said Dr Mohamed Shamji, Head of the Immunomodulation and Tolerance Group, Imperial College London.

Stallergenes Greer Showcases Precision Medicine at 2021 EAACI Congress

Retrieved on: 
Sunday, July 11, 2021
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Immunology, Medicine, Allergology, Stallergenes Greer, Allergen immunotherapy, Personalized medicine, European Academy of Allergy and Clinical Immunology, Ait, Allergen, Precision medicine, Allergy

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), announces that the company showcased its advancements in precision medicine in AIT via a company sponsored symposium entitled Supporting individual patients needs: AIT still an unmatched model of personalized medicine for allergy at the European Academy of Allergy and Clinical Immunology (EAACI) 2021 Congress in Krakow (Poland).

Key Points: 
  • Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), announces that the company showcased its advancements in precision medicine in AIT via a company sponsored symposium entitled Supporting individual patients needs: AIT still an unmatched model of personalized medicine for allergy at the European Academy of Allergy and Clinical Immunology (EAACI) 2021 Congress in Krakow (Poland).
  • Stallergenes Greer is present at the congress from July 10 to July 12 and will also present nine posters addressing precision medicine in AIT and announcing new data from clinical trials and real-world studies.
  • Precision medicine is paving the way to the future of allergen immunotherapy by exploring the mechanism of disease of each individual to provide patients with precise, personalised and targeted treatment approaches.
  • Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).

Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy

Retrieved on: 
Friday, July 9, 2021
Health, Infectious diseases, Clinical trials, Research, Pharmaceutical, Science, Medical specialties, Allergology, Medicine, Clinical medicine, Stallergenes Greer, Ait, Allergen immunotherapy, Precision medicine

Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), and Alyatec, a contract research organisation based in Strasbourg University Hospital (France), today announced that they have entered into a collaboration to advance precision medicine in AIT.

Key Points: 
  • Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy (AIT), and Alyatec, a contract research organisation based in Strasbourg University Hospital (France), today announced that they have entered into a collaboration to advance precision medicine in AIT.
  • This research collaboration brings together the longstanding expertise of Stallergenes Greer in AIT and Alyatecs competencies in research and clinical services as well as its state-of-the-art technology, including a new generation environmental exposure chamber.
  • We are excited about the collaboration with Alyatec which will support Stallergenes Greers ambition to advance the practice of allergology.
  • This collaboration is a remarkable opportunity for Alyatec to develop precision medicine in AIT.

Stallergenes Greer: Alustal®, the Company’s Subcutaneous Allergen Immunotherapy Treatment (SCIT) Now Available

Retrieved on: 
Thursday, June 24, 2021
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Medical specialties, Immunology, Clinical medicine, Allergology, Stallergenes Greer, SCIT, Allergen immunotherapy, Allergen, Allergy, Immunotherapy, HAL Allergy Group

Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces that Alustal, its subcutaneous allergen immunotherapy (SCIT) solution, is now available in Italy and Spain following the full resumption of SCIT production in Antony (France).

Key Points: 
  • Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces that Alustal, its subcutaneous allergen immunotherapy (SCIT) solution, is now available in Italy and Spain following the full resumption of SCIT production in Antony (France).
  • Alustal will be also available in Australia, France and Switzerland in the coming months.
  • View the full release here: https://www.businesswire.com/news/home/20210624005500/en/
    We are pleased that patients and the medical community have access to an alternative allergen immunotherapy option with Alustal.
  • Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services.